Champions Oncology Reports Record Quarterly Revenue of $11.3 Million

Rhea-AI Summary

Champions Oncology (CSBR) reported record revenue of $11.3 million for Q1 FY2022, marking an 18% increase year-over-year. The company achieved a non-GAAP income of $422,000, while operational losses were $175,000, impacted by increased R&D expenses. Total costs rose 20% to $11.4 million. Gross margins improved to 52% due to internalizing lab work. The firm continues to expand its Software as a Service (SaaS) offerings and therapeutic target discovery initiatives, ending the quarter with a solid cash position of $4 million.

Positive

• Record revenue of $11.3 million for Q1 FY2022, an 18% increase YoY.
• Non-GAAP income from operations of $422,000.
• Gross margin improved to 52%, up from 44.1% YoY.
• Strong cash position of $4 million with no debt.

Negative

• Loss from operations of $175,000 compared to a profit of $24,000 YoY.
• Total costs increased by 20% to $11.4 million.

HACKENSACK, NJ / ACCESSWIRE / September 13, 2021 / Champions Oncology, Inc. (Nasdaq:CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 2022, ended July 31, 2021.

First Quarter and Recent Highlights:

• Record quarterly revenue of $11.3 million, an increase of 18% year over year
• Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $422,000
• Validated 6 therapeutic discovery targets

Ronnie Morris, CEO of Champions, commented, "On our year-end earnings call, we outlined the transformative strategic vision for Champions with the expansion of our services to include a Software as a Service ("SaaS") business and therapeutic target discovery platform. During the first quarter, we continued executing that strategy as we added new users to our SaaS platform and by advancing our therapeutic targets through the development pipeline."

David Miller, CFO of Champions, added, "During Q1 2022, we hit another quarterly revenue record surpassing $11 million for the first time. Operating income excluding stock compensation and depreciation expenses exceeded $400,000 even as we ramped up our R&D investment to support our new strategic initiatives."

First Fiscal Quarter Financial Results

For the first quarter of fiscal 2022, revenue increased 17.9% to $11.3 million compared to $9.5 million for the first quarter of fiscal 2021. The increase in revenue was due to a continued increase in sales, both in number and size of studies, and the expansion of our platforms and business lines. Total costs and operating expenses for the first quarter of fiscal 2022 were $11.4 million compared to $9.5 million for the first quarter of fiscal 2021, an increase of $1.9 million or 20.0%.

For the first quarter of fiscal 2022, Champions reported a loss from operations of $175,000, including $280,000 in stock-based compensation and $317,000 in depreciation and amortization expenses, compared to income from operations of $24,000, inclusive of $120,000 in stock-based compensation and $277,000 in depreciation and amortization expenses, in the first quarter of fiscal 2021. Excluding stock-based compensation, depreciation and amortization expenses, Champions reported non-GAAP income from operations of $422,000 for the first quarter of fiscal 2022 compared to non-GAAP income from operations of $421,000 in the first quarter of fiscal 2021.

Cost of oncology solutions was $5.4 million for the three-months ended July 31, 2021, an increase of $60,000, or 1.1% compared to $5.3 million for the three-months ended July 31, 2020. For the three- months ended July 31, 2021, gross margin was 52.0% compared to 44.1% for the three-months ended July 31, 2020. The nominal increase in cost of sales was primarily due to reducing our reliance on outsourcing lab work by performing the work internally. The associated cost reduction offset the increase in compensation and lab supply expenses resulting from the increase in study volume. The nominal increase in cost of sales on revenue growth of $1.7 million led to the improvement in gross margin.

Research and development expense for the three-months ended July 31, 2021 was $2.3 million, an increase of $707,000 or 44.3%, compared to $1.6 million for the three-months ended July 31, 2020. The increase was primarily from compensation and lab supplies as we increased investment in our therapeutic discovery platforms. Sales and marketing expense for the three-months ended July 31, 2021 was $1.6 million, an increase of $366,000, or 30.3%, compared to $1.2 million for the three-months ended July 31, 2020. The increase was primarily due to compensation expense driven by the continued investment in expanding our business development team, including the addition of a dedicated SaaS business development team for our Lumin Bioinformatics platform. General and administrative expense for the three-months ended July 31, 2021 was $2.2 million, an increase of $772,000, or 55.9%, compared to $1.4 million for the three-months ended July 31, 2020. The increase was primarily due to an increase in compensation, which included $123,000 of additional stock compensation expense, as well as an increase in IT related expenses and depreciation and amortization.

Net cash provided by operating activities was $216,000 for the three-months ended July 31, 2021.The cash generated from operating activities was primarily due to operating income excluding stock compensation, depreciation and amortization expenses.

The Company ended the quarter with a strong cash position of $4.0 million. The Company has no debt.

Conference Call Information:

The Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its first quarter financial results. To participate in the call, please call 844-602-0380 (domestic) or 862-298-0970 (international) ten minutes ahead of the call and give the verbal reference "Champions Oncology."

Full details of the Company's financial results will be available by Tuesday, September 14, 2021 in the Company's Form 10-Q at www.championsoncology.com.

* Non-GAAP Financial Information

See the attached Reconciliation of GAAP net income (loss) to Non-GAAP net income for an explanation of the amounts excluded to arrive at Non-GAAP net income and related Non-GAAP earnings per share amounts for the three months ended July 31, 2021 and 2020. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net income and Non-GAAP earnings per share are not, and should not, be viewed as a substitute for similar GAAP items. Champions defines Non-GAAP dilutive earnings per share amounts as Non-GAAP net earnings divided by the weighted average number of diluted shares outstanding. Champions' definition of Non-GAAP net earnings and Non-GAAP diluted earnings per share may differ from similarly named measures used by other companies.

About Champions Oncology, Inc.

Champions Oncology is a data-driven research organization, with headquarters in the United States, that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex-vivo and biomarker platforms. For more information, please visit www.ChampionsOncology.com.

This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2021 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.

Media Contact:
Rachel Bunting, MS, MBA
Sr. Director, Head of Marketing
Marketing@ChampionsOncology.com

Champions Oncology, Inc.
(Dollars in thousands)

Reconciliation of GAAP to Non-GAAP Net Income (Unaudited)

		Three Months Ended July 31,
		2021				2020
Net income(loss) - GAAP		$	(172	)		$	75
Less:
Stock-based compensation			280				120
Net income - Non-GAAP		$	108			$	195

Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)

		Three Months Ended July 31,
		2021				2020
EPS - GAAP, basic		$	(0.01	)		$	0.01
Less:
Effect of stock-based compensation on EPS			0.02				0.01
EPS - Non-GAAP, basic		$	0.01			$	0.02

		Three Months Ended July 31,
		2021				2020
EPS - GAAP, diluted		$	(0.01	)		$	0.01
Less:
Effect of stock-based compensation on EPS			0.02				0.01
EPS - Non-GAAP, diluted		$	0.01			$	0.02

Unaudited Condensed Consolidated Statements of Operations (unaudited)

		Three Months Ended July 31,
		2021				2020
Oncology services revenue		$	11,253			$	9,547
Cost of oncology services			5,396				5,336
Research and development			2,304				1,597
Sales and marketing			1,574				1,208
General and administrative			2,154				1,382
Income (loss) from operations			(175	)			24
Other income			17				64
Income (loss) before provision for income taxes			(158	)			88
Provision for income taxes			14				13
Net income (loss)		$	(172	)		$	75
Net income (loss) per common share outstanding
basic		$	(0.01	)		$	0.01
and diluted		$	(0.01	)		$	0.01
Weighted average common shares outstanding
basic			13,401,929				12,727,275
and diluted			13,401,929				14,231,641

Condensed Consolidated Balance Sheets

		July 31, 2021				April 30, 2021
		(unaudited)
Cash		$	3,998			$	4,687
Accounts receivable, net			7,733				6,986
Other current assets			864				957
Total current assets			12,595				12,630
Operating lease right-of-use assets, net			8,329				8,521
Property and equipment, net			6,763				6,090
Other long term assets			86				15
Goodwill			335				335
Total assets		$	28,108			$	27,591
Accounts payable and accrued liabilities		$	5,326			$	4,125
Current portion of operating lease liabilities			854				818
Other current liabilities			15				-
Deferred revenue			5,481				6,256
Total current liabilities			11,676				11,199
Non-current operating lease liabilities			8,652				8,783
Other Non-current Liability			242				181
Total liabilities			20,570				20,163
Stockholders' equity			7,538				7,428
Total liabilities and stockholders' equity		$	28,108			$	27,591

Unaudited Condensed Consolidated Statements of Cash Flows (unaudited)

		Three Months Ended July 31,
		2021				2020
Cash flows from operating activities:
Net income (loss)		$	(172	)		$	75
Adjustments to reconcile net income to net cash provided by operations:
Stock-based compensation expense			280				120
Operating lease right-of use assets			245				(67	)
Depreciation and amortization expense			317				277
Gain on termination of operating lease			-				(75	)
Net gain on disposal of equipment			(4	)			-
Allowance for doubtful accounts			78				(6	)
Changes in operating assets and liabilities			(528	)			(1,039	)
Net cash provided by operating activities			216				(715	)
Cash flows from investing activities:
Purchases of property and equipment			(907	)			(718	)
Refund of security deposit			-				92
Net cash used in investing activities:			(907	)			(626	)
Cash flows from financing activities:
Proceeds from the exercise of stock options			2				-
Finance lease payments			-				(58	)
Net cash provided by financing activities:			2				(58	)
Net increase (decrease) in cash			(689	)			(1,399	)
Cash at beginning of period			4,687				8,342
Cash at the end of period		$	3,998			$	6,943
Non-cash investing activities:
Right-of-use assets obtained in exchange for operating lease liabilities			-				3,872
Equipment acquired in accounts payable			79				-

SOURCE: Champions Oncology, Inc.

View source version on accesswire.com:
https://www.accesswire.com/663706/Champions-Oncology-Reports-Record-Quarterly-Revenue-of-113-Million

FAQ

What were Champions Oncology's Q1 FY2022 financial results?

Champions Oncology reported record revenue of $11.3 million, an 18% increase year-over-year, and a non-GAAP income from operations of $422,000.

What is the stock symbol for Champions Oncology?

The stock symbol for Champions Oncology is CSBR.

What factors contributed to the increase in revenue for CSBR?

The revenue increase was attributed to a rise in the number and size of studies, along with expansion in their platforms and business lines.

How did Champions Oncology's gross margin change in Q1 FY2022?

The gross margin improved to 52% for Q1 FY2022, up from 44.1% in the previous year.

What was the cash position for Champions Oncology at the end of Q1 FY2022?

Champions Oncology ended Q1 FY2022 with a strong cash position of $4 million and no debt.